Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

49 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Author Correction: IL-12 reprograms CAR-expressing natural killer T cells to long-lived Th1-polarized cells with potent antitumor activity.
Landoni E, Woodcock MG, Barragan G, Casirati G, Cinella V, Stucchi S, Flick LM, Withers TA, Hudson H, Casorati G, Dellabona P, Genovese P, Savoldo B, Metelitsa LS, Dotti G. Landoni E, et al. Among authors: metelitsa ls. Nat Commun. 2024 Jun 18;15(1):5182. doi: 10.1038/s41467-024-49582-6. Nat Commun. 2024. PMID: 38890345 Free PMC article. No abstract available.
Interleukin-15-armored GPC3-CAR T cells for patients with solid cancers.
Steffin D, Ghatwai N, Montalbano A, Rathi P, Courtney AN, Arnett AB, Fleurence J, Sweidan R, Wang T, Zhang H, Masand P, Maris JM, Martinez D, Pogoriler J, Varadarajan N, Thakkar SG, Lyon D, Lapteva N, Mei Z, Patel K, Lopez-Terrada D, Ramos C, Lulla P, Armaghany T, Grilley BJ, Dotti G, Metelitsa LS, Heslop HE, Brenner MK, Sumazin P, Heczey A. Steffin D, et al. Among authors: metelitsa ls. Res Sq [Preprint]. 2024 Apr 3:rs.3.rs-4103623. doi: 10.21203/rs.3.rs-4103623/v1. Res Sq. 2024. PMID: 38645165 Free PMC article. Preprint.
CAR-redirected natural killer T cells demonstrate superior antitumor activity to CAR-T cells through multimodal CD1d-dependent mechanisms.
Zhou X, Wang Y, Dou Z, Delfanti G, Tsahouridis O, Pellegry CM, Zingarelli M, Atassi G, Woodcock MG, Casorati G, Dellabona P, Kim WY, Guo L, Savoldo B, Tsagaratou A, Milner JJ, Metelitsa LS, Dotti G. Zhou X, et al. Among authors: metelitsa ls. Nat Cancer. 2024 Oct 1. doi: 10.1038/s43018-024-00830-0. Online ahead of print. Nat Cancer. 2024. PMID: 39354225
A milestone method to make natural killer T cells.
Metelitsa LS. Metelitsa LS. Nat Biotechnol. 2024 May 14. doi: 10.1038/s41587-024-02243-x. Online ahead of print. Nat Biotechnol. 2024. PMID: 38744945 No abstract available.
Author Correction: Anti-GD2 CAR-NKT cells in relapsed or refractory neuroblastoma: updated phase 1 trial interim results.
Heczey A, Xu X, Courtney AN, Tian G, Barragan GA, Guo L, Amador CM, Ghatwai N, Rathi P, Wood MS, Li Y, Zhang C, Demberg T, Di Pierro EJ, Sher AC, Zhang H, Mehta B, Thakkar SG, Grilley B, Wang T, Weiss BD, Montalbano A, Subramaniam M, Xu C, Sachar C, Wells DK, Dotti G, Metelitsa LS. Heczey A, et al. Among authors: metelitsa ls. Nat Med. 2024 Apr;30(4):1210. doi: 10.1038/s41591-024-02799-w. Nat Med. 2024. PMID: 38195754 No abstract available.
IL-12 reprograms CAR-expressing natural killer T cells to long-lived Th1-polarized cells with potent antitumor activity.
Landoni E, Woodcock MG, Barragan G, Casirati G, Cinella V, Stucchi S, Flick LM, Withers TA, Hudson H, Casorati G, Dellabona P, Genovese P, Savoldo B, Metelitsa LS, Dotti G. Landoni E, et al. Among authors: metelitsa ls. Nat Commun. 2024 Jan 2;15(1):89. doi: 10.1038/s41467-023-44310-y. Nat Commun. 2024. PMID: 38167707 Free PMC article.
Anti-GD2 CAR-NKT cells in relapsed or refractory neuroblastoma: updated phase 1 trial interim results.
Heczey A, Xu X, Courtney AN, Tian G, Barragan GA, Guo L, Amador CM, Ghatwai N, Rathi P, Wood MS, Li Y, Zhang C, Demberg T, Di Pierro EJ, Sher AC, Zhang H, Mehta B, Thakkar SG, Grilley B, Wang T, Weiss BD, Montalbano A, Subramaniam M, Xu C, Sachar C, Wells DK, Dotti G, Metelitsa LS. Heczey A, et al. Among authors: metelitsa ls. Nat Med. 2023 Jun;29(6):1379-1388. doi: 10.1038/s41591-023-02363-y. Epub 2023 May 15. Nat Med. 2023. PMID: 37188782 Clinical Trial.
LEF1 Drives a Central Memory Program and Supports Antitumor Activity of Natural Killer T Cells.
Ngai H, Barragan GA, Tian G, Balzeau JC, Zhang C, Courtney AN, Guo L, Xu X, Wood MS, Drabek JM, Demberg T, Sands CM, Chauvin-Fleurence CN, Di Pierro EJ, Rosen JM, Metelitsa LS. Ngai H, et al. Among authors: metelitsa ls. Cancer Immunol Res. 2023 Feb 3;11(2):171-183. doi: 10.1158/2326-6066.CIR-22-0333. Cancer Immunol Res. 2023. PMID: 36484736 Free PMC article.
49 results